Decision: Favourable

Study Title:

A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Prof Orla Hardiman

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Amylyx Pharmaceuticals Inc

Scroll to Top